SingleMetabolic / GLP-1

Cagrilintide 10mg

A long-acting synthetic amylin analogue investigated for neuroendocrine satiety signaling, gastric kinetics, and body composition regulation.

Mechanism

Functions as a long-acting amylin and calcitonin receptor agonist that decelerates gastric emptying and triggers central hypothalamic satiety pathways to suppress appetite.

Dosing

Standard laboratory titration initiates at a documented starting dose of 0.25 mg administered subcutaneously once per week.

Reconstitution

Reconstituting a 10 mg vial with 2.0 mL of bacteriostatic water yields a peptide concentration of 5 mg/mL.

Storage

Store the unmixed lyophilized vial frozen at -20 °C, and refrigerate the reconstituted solution between 2 °C and 8 °C for use within 2 to 4 weeks.

Mix & measure Cagrilintide 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Cagrilintide 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration5.00mg/mL

Draw volume0.050mL

On the syringe5.00units

Total doses in vial: 40.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	0.25 mg once weekly	5 units (0.05 mL)
Weeks 3–4	0.5 mg once weekly	10 units (0.10 mL)
Weeks 5–8	1.0 mg once weekly	20 units (0.20 mL)
Weeks 9–12	1.7 mg once weekly	34 units (0.34 mL)
Weeks 13–16	2.4 mg once weekly	48 units (0.48 mL)

Reconstitution Steps

1
Clean the rubber septum of the 10 mg Cagrilintide vial using an alcohol prep pad and allow it to air-dry completely.
2
Draw exactly 2.0 mL of bacteriostatic water into a sterile syringe.
3
Insert the needle at a slight angle and direct the stream gently down the glass wall of the vial to minimize agitation and foaming.
4
Swirl the vial with smooth, slow motions until the lyophilized cake is fully dissolved; avoid vigorous shaking.
5
Date the vial and transfer it immediately into dark refrigeration maintained between 2 °C and 8 °C.

Supplies Needed

Peptide Vial

Lyophilized Cagrilintide (10 mg) providing research-grade active peptide material.

Insulin Syringes (U-100)

Accurately measuring fractional milliliter volumes for subcutaneous delivery.

Bacteriostatic Water

2.0 mL used as the reconstituting antimicrobial diluent for stable storage.

Alcohol Swabs

Aseptic disinfection of vial stoppers and injection sites prior to administration.

Why researchers study it

Weight management and metabolic regulation models

Hypothalamic appetite suppression and satiety signaling

Deceleration of gastric emptying kinetics

Dual-agonist synergy in combination with GLP-1 analogues

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Cagrilintide is an investigational, long-acting synthetic analogue of human amylin engineered with fatty acid acylation to provide sustained receptor activation. Endogenous amylin is typically released alongside insulin from pancreatic beta cells to regulate nutrient influx. By functioning as a high-potency agonist across both amylin and calcitonin receptors, cagrilintide plays a fundamental role in laboratory research addressing centralized energy homeostasis, appetite modulation, and non-insulin-dependent glycemic stabilization. Preclinical and clinical trial data highlight its unique pharmacological profile, distinguishing it from conventional incretin mimetics while demonstrating potent synergy when co-administered with GLP-1 receptor agonists like semaglutide. In research models, the peptide consistently prolongs inter-meal satiety intervals, mitigates hedonic feeding drives, and decelerates stomach emptying without compromising lean tissue mass under controlled nutritional conditions.

References

1.Lau et al., The Lancet, 2021 — Once-weekly cagrilintide for weight management: a randomised, double-blind, phase 2, dose-finding trial
2.Enebo et al., The Lancet, 2021 — Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide plus semaglutide in individuals with overweight or obesity
3.Kruse et al., Journal of Medicinal Chemistry, 2021 — Discovery and development of cagrilintide, a long-acting amylin analogue
4.Dehestani et al., Clinical Pharmacokinetics, 2024 — Clinical pharmacokinetics of cagrilintide and long-acting amylin analogues